Clinical trial
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
NCT00114777 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00114777 |
|---|---|
| Title | Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant |
| Official title | Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT) |
| Acronym | BENEFIT-EXT |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Renal Transplantation |
| Intervention type | Drug |
| Interventions | Cyclosporin A, Belatacept Less Intensive Regimen (LI), Belatacept More Intensive Regimen (MI) |
| Enrollment | 595 |
| Start date | Feb 1, 2005 |
| Primary completion | May 1, 2008 |
| Completion | Sep 1, 2014 |
| First posted | Jun 20, 2005 |
| Last update posted | Jul 7, 2017 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Czechia, France, Germany, Hungary, Italy and 7 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: